Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $39.67.
PHAR has been the subject of several analyst reports. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Wednesday, October 28th. Wall Street Zen raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Sunday, November 1st. Canaccord Genuity Group boosted their target price on shares of Pharming Group from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Weiss Ratings raised shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, November 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, September 22nd.
Read Our Latest Analysis on PHAR
Pharming Group Stock Down 5.2%
Shares of NASDAQ PHAR opened at $11.54 on Friday. The company has a 50 day simple moving average of $11.06 and a 200 day simple moving average of $13.31. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.23 and a quick ratio of 2.65. Pharming Group has a 1 year low of $9.11 and a 1 year high of $21.34. The firm has a market cap of $816.80 million, a PE ratio of 36.06 and a beta of -0.05.
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. The business had revenue of $117.60 million during the quarter, compared to the consensus estimate of $117.60 million. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. On average, research analysts forecast that Pharming Group will post 0.34 EPS for the current year.
Hedge Funds Weigh In On Pharming Group
An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP bought a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up about 6.0% of MAC Alpha Capital Management LP’s holdings, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.03% of the company’s stock.
Pharming Group Company Profile
Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Recommended Stories
- Five stocks we like better than Pharming Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
